title: Inhibition of angiogenesis: thalidomide or low-molecular-weight heparin?
authors.forename: Metin
authors.initials: M
authors.lastname: Ozkan
authors.forename: Bulent
authors.initials: B
authors.lastname: Eser
authors.forename: Ozlem
authors.initials: O
authors.lastname: Er
authors.forename: Gamze Gokoz
authors.initials: GG
authors.lastname: Dogu
authors.forename: Mustafa
authors.initials: M
authors.lastname: Altinbas
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000925:Anticoagulants / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013792:Thalidomide / Q000627:therapeutic use*
chemical_list: D020533:Angiogenesis Inhibitors; D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D013792:Thalidomide